Literature DB >> 2650990

The complement profile in clinical medicine. Inherited and acquired conditions lowering the serum concentrations of complement component and control proteins.

C D West1.   

Abstract

The serum complement profile of patients with systemic or discoid lupus erythematosus, synovitis, vasculitides, certain recurrent or chronic skin rashes, recurrent or fulminant infections, particularly with Neisseria, may reveal homozygous deficiencies of complement components causally related to the illness. The nephritis of systemic lupus erythematosus (SLE) is often accompanied by a distinctive complement profile which indicates classical pathway activation and which can be used as an index of the success of treatment. In membranoproliferative glomerulonephritis (MPGN), the hypocomplementemia may reflect classical pathway activation in type I, the nephritic factor of the amplification loop in type II, or a nephritic factor activating terminal components in type III. In acute poststreptococcal glomerulonephritis, the cause of the hypocomplementemia is not known but the profile usually differs from that of MPGN or SLE. In these acquired hypocomplementemias, the profile supplements the renal biopsy in providing diagnostic information.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2650990

Source DB:  PubMed          Journal:  Complement Inflamm        ISSN: 1012-8204


  4 in total

Review 1.  The role of necrotic cell death in the pathogenesis of immune mediated nephropathies.

Authors:  Neelakshi R Jog; Roberto Caricchio
Journal:  Clin Immunol       Date:  2014-05-17       Impact factor: 3.969

Review 2.  Clinical utility of complement assessment.

Authors:  A E Ahmed; J B Peter
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

Review 3.  Idiopathic membranoproliferative glomerulonephritis in childhood.

Authors:  C D West
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

Review 4.  Complement as a Therapeutic Target in Systemic Autoimmune Diseases.

Authors:  María Galindo-Izquierdo; José Luis Pablos Alvarez
Journal:  Cells       Date:  2021-01-13       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.